MAS
BBIO icon

Meeder Advisory Services’s BridgeBio Pharma BBIO Stock Holding History

Meeder Advisory Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Sell
3,657
-195
-5% -$13.7K 0.01% 589
2026
Q1 		$286K Buy
3,852
+56
+1% +$4.06K 0.01% 531
2025
Q4 		$290K Buy
+3,796
New +$249K 0.01% 539

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Meeder Advisory Services's BBIO Position: Q2 2026 in Review

Meeder Advisory Services reduced its BridgeBio Pharma (BBIO) stake by 5.1% in Q2 2026, selling an estimated $13.7K and leaving 3,657 shares worth $272K. The position accounts for 0.01% of the portfolio, ranked #589.

Meeder Advisory Services first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $290K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Meeder Advisory Services held 3,657 shares of BridgeBio Pharma worth $272K as of Q2 2026.
  • Meeder Advisory Services sold 195 BridgeBio Pharma shares in Q2 2026, an estimated $13.7K.
  • BridgeBio Pharma made up 0.01% of Meeder Advisory Services's portfolio in Q2 2026, its #589 holding.
  • Meeder Advisory Services first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Meeder Advisory Services's BridgeBio Pharma position peaked at $290K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Meeder Advisory Services's 13F filing for Q2 2026, filed 7 Aug 2026.